News Archive

Walbrook PR AQSE IPO – ProBiotix Health PLC

31 March 2022

Walbrook PR, one of the UK’s leading providers of Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it has acted as Financial PR & Investor Relations advisor for the Aquis Stock Exchange (“AQSE”) IPO of ProBiotix Health plc (“ProBiotix”), the life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions. ProBiotix was established by AIM-listed OptiBiotix Health plc to develop next-generation microbiome solutions for a wide range of health conditions and to deliver commercially successful products supported by a strong scientific evidence base.

On admission, ProBiotix raised £2.5 million through a placing and subscription, giving the Company a market capitalisation of approximately £25.5 million and trade under the ticker PBX.

The AQSE Growth Market, the UK’s only competitor equities exchange to the LSE, has undergone a major transformation over the last couple of years. Spreads have reduced, access has improved, and turnover has risen. In 2021, 24 IPOs were completed on AQSE and some £100m was raised.

The Directors of ProBiotix believe that an investment in the Company represents an opportunity to invest in an innovative technology that is underpinned by a significant portfolio of Intellectual Property Rights, supported by an experienced board, and applicable to a range of markets.

The team at Walbrook will now manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.

Paul McManus, Founder and Managing Director of Walbrook PR, commented: “We are delighted to work with ProBiotix and congratulate the Company on their AQSE IPO today. This IPO represents a landmark moment for ProBiotix as an independent company in its own right, and we look forward to developing the Company’s profile with analysts, investors and journalists as they begin this exciting new journey.”


For more information visit the Company’s website:


For further information please contact:

Paul McManus Tel: 020 7933 8787 Mob: 07980 541 893 [email protected] or [email protected]


About Walbrook PR:                                                                                                                                  

Walbrook PR was founded in April 2009 by Paul McManus and focuses on providing high quality Financial PR and Investor Relations to Small Cap and AIM listed companies.

Walbrook PR is ranked #3 by number of AIM listed companies with 51 AIM listed clients (Source: AIM Advisers Rankings Guide, January 2022), ranked #1 for life sciences and #7 by total number of stock market listed clients (Corporate Advisers Rankings Guide, February 2022) advising a total of 58 stock market listed companies across a wide mix of sectors.

Walbrook PR prides itself on having a strong reputation for working with growing UK Small Cap and AIM listed companies; a proven IR offering, which focuses on the Private Client Investment Management community and the retail investment community; and on having a proactive, hands-on approach from a committed team with full ownership of the business.

Who We Work With